Tag: Johnson & Johnson
J&J Subsidiary Seeks EU Approval for Nanocrystal Based Schizophrenia Drug
by Kevin Rippey on Dec.07, 2009, under Nanotech Company Info, Pharmaceuticals
Janssen-Cilag a division of Johnson & Johnson (NYSE: JNJ) has submitted a marketing application for paliperidone palmitate (marketed as Invega Sustenna in the US) a once-montly schizophrenia treatment that utilizes Elan’s (NYSE: ELN) Nanocrystal drug delievery system. The treatment was granted approval by the FDA in August. The monthly injection is seen as having certian advantages over oral drug treatments. Specifically, paliperidone palmitate avoids the potential for relapse as result of individual’s failing to take their medication (a common outcome of oral-based schezophrenia treatments).
Full Story: Here
J&J partnered with Elan following a $1 billion investment by the New Jersey health care giant earlier this year. In return for the investment J&J recieved an 18.34% stake in the Dublin based biotech company and rights to teh biotech’s Immunotherapy Program.
Full Story: Here
